Geist has more than 25 years of experience and most recently served as VP and general manager for Thermo Fisher Scientific’s protein and cell analysis and qPCR business units. He also held numerous sales, marketing and business development leadership roles at Qiagen’s Quanta BioSciences.
“Quanterix is experiencing strong momentum across numerous digital biomarker platforms supporting drug development and non-invasive, early disease diagnostics research,” president and CEO Kevin Hrusovsky said in a news release. “We are extremely fortunate to attract Will into Quanterix at this important time given his wealth of operating experience and track record for growing revenue and profitability, both commercially and operationally.”
Geist will be responsible for the execution and continued growth of the company’s ultra-sensitive Simoa technology, including its neurology franchise.
“I am very excited to join Quanterix during this phase of growth and expansion,” Geist said. “I have long admired the company’s mission and execution and welcome the opportunity to further operationalize and scale the innovation Quanterix continues to achieve as part of its vision for precision health.”